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Ribozymes are catalytic RNAs that offer several advantages as specific therapeutic genes against human immunodefi-
ciency virus type 1 (HIV-1). Significant challenges in antiviral uses of ribozymes include (1) how best to express and to deliver
this agent and (2) what is the best locale to target ribozymes against HIV-1 RNA. To explore the former, we have previously
characterized several vector systems for efficient expression/delivery of anti-HIV-1 ribozymes (Dropulic et al., 1992; Dropulic
and Jeang, 1994a; Smith et al., 1997). Here, to investigate an optimal locale for ribozyme-targeting, we asked whether it might
be advantageous to direct ribozymes into HIV-1 virions as opposed to the more conventional approach of targeting ribozymes
into infected cells. Two series of experiments were performed. First, we demonstrated that anti-HIV-1 ribozymes could
indeed be packaged specifically and efficiently into virions. Second, we compared the virus suppressing activity of a
packageable ribozyme with its counterpart, which cannot be packaged into HIV-1 virions. Our results showed that although
both ribozymes cleaved HIV-1 genomic RNA in vitro with equivalent efficiencies, the former ribozyme demonstrated
significantly higher virus-suppressing activity than the latter. These findings provide proof-of-principle that to combat
productive HIV-1 replication, intravirion targeting is more effective than intracellular targeting of ribozymes. © 2000 Academic
Press
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oINTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) estab-
lishes a chronic in vivo infection that is accompanied by
progressive destruction or suppression of susceptible
CD41 T lymphocytes, leading eventually to a profound
depletion of critical immune cells. Sustained turnovers of
HIV-1 occur in infected individuals at all stages of infec-
tion (Stevenson et al., 1988; Piatak et al., 1993; Coffin,
995). To interrupt this process, chemotherapeutic anti-
IV agents such as inhibitors of reverse transcriptase
nd/or protease are capable of decreasing viral replica-
ion by 1–3 logs or more (Coffin, 1995). However, these
gents must be administered multiple times per day and
ave significant toxicity and uncertain long-term effica-
ies (Leavitt et al., 1996). Thus there remains a pressing
need for the development of additional molecular anti-
HIV-1 agents. Indeed, various molecular approaches
against HIV-1 (reviewed in Dropulic and Jeang, 1994),
including transdominant negative proteins (Li et al.,
1994), intracellular single-chain antibody (Marasco et al.,
1993), RNA decoys (Lisziewicz et al., 1993; Dropulic et al.,
1994), and ribozymes (Akhtar and Rossi, 1995), have
been proposed.
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174Ribozymes are catalytic antisense molecules that can
cleave RNAs (Cech, 1987; Symons, 1992; Haseloff and
Gerlach, 1998). Many different types of ribozymes exist.
Among the different ribozymes, those with hammerhead
or hairpin motifs have been studied extensively as anti-
viral agents (Yu et al., 1995; Xing et al., 1995; James and
Gibson, 1998). Several hammerhead and hairpin ri-
bozymes have been targeted experimentally to various
sites in the HIV genome (Sarver et al., 1990; Ho et al.,
1995; Zhou et al., 1996; Gervaix et al., 1997), and previ-
usly, we characterized some vector systems for high-
evel expression of anti-HIV-1 hammerhead ribozymes
Dropulic et al., 1992; Dropulic and Jeang, 1994a; Smith et
l., 1997). Here, to address optimal delivery of anti-HIV-1
ibozymes, we asked whether it might be advantageous
o target ribozymes into HIV-1-virions rather than into
IV-1-infected cells. For this purpose, we took advantage
f a cell line (Srinivasakumar et al., 1997) that produces
HIV-1 structural proteins that efficiently package HIV-
derived vector RNA. Such a packaging line can be used
to generate RNA-containing HIV-1 particles capable of
infecting CD41 target cells. Using this packaging cell, we
checked whether anti-HIV-1 ribozymes could be incorpo-
rated specifically and efficiently into virions.
To deliver ribozymes into virions, we linked a catalytic
hammerhead motif to a portion of the HIV-1 genome that
provided a packaging sequence. The virus-suppressing
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175ANTI-HIV RIBOZYMEactivity of a packageable ribozyme was then compared
with a counterpart ribozyme that could not be packaged
into virions. In side-by-side comparisons, we observed
that although both types of ribozyme cleaved HIV-1
genomic RNA with comparable in vitro efficiency, the
irion-incorporated ribozyme showed significantly higher
irus-suppressing activity than its nonpackageable coun-
erpart. Our findings suggest that in combating HIV-1,
ibozymes targeted into virions are more effective than
hose targeted into cells.
RESULTS
pecific cleavage of HIV-1 RNA by ribozymes in vitro
Hammerhead ribozymes cleave RNAs at a GUCN con-
ensus sequence. Eleven GUCU targets are present in
he HIV-1 genomic RNA (Dropulic et al., 1992). We de-
igned a ribozyme (RibPol; Fig. 1) targeted to one such
UCU in pol at nucleotide 4141. The intention was to
reate a pol-specific ribozyme that could be expressed in
format (Fig. 1) for incorporation into HIV-1 virions. The
ol ribozyme was engineered to contain a hammerhead
atalytic domain flanked by 10 and 17 nucleotides that
re complementary to sequences 59 and 39 to the GUCU
leavage site, respectively (Fig. 2).
The cleavage specificity of the pol ribozyme was as-
essed first in vitro. To transcribe pol ribozyme in vitro,
he ribozyme sequence was positioned into a plasmid
ownstream of a T7 promoter (pGEM-4Z-RibPol; see Ma-
erials and Methods and Fig. 2). We also constructed
nother plasmid that directed the in vitro synthesis by T7
NA polymerase of the substrate RNA for the pol ri-
ozyme. When a-32P-UTP-labeled ribozyme and sub-
trate transcripts were mixed at a 1:1 ratio, the substrate
FIG. 1. Schematic representations of HIV vectors containing the
hygromycin B resistance gene and the HIV-1-cleaving ribozyme (Rib-
Pol). (Top) A representation of the pNL4-3 genome with overlying open
reading frames. The 59 and 39 LTRs and restriction enzyme sites
relevant to the construction of vectors are indicated. (Middle) Thep
pTR167 vector. (Bottom) pTR167RibPol, a derivative of pTR167 that
contains the pol ribozyme (RibPol).NA was specifically cleaved into the two expected
roduct fragments (P1 and P2; Fig. 2B). Maximum in vitro
leavage occurred within 5 min. Previously, we have
hown that hammerhead ribozymes behave as modular
lements in the context of a full-length HIV-1 genome
Dropulic et al., 1992; Smith et al., 1997). Indeed, this pol
ibozyme was demonstrated to be wholly active when
laced within a pNL4-3 genome (Dropulic and Jeang,
994b).
ntravirion packaging of a functional ribozyme
FIG. 2. In vitro cleavage of an HIV-1 pol-RNA substrate by the pol
ibozyme. (A) Schematic representations of the T7 promoter-driven
lasmids that direct the synthesis of the substrate (upper) and ri-
ozyme (lower) RNAs. An inset shows only the relevant interactive
equences between the substrate and the ribozyme, middle. (B) Kinet-
cs of cleavage of the substrate (S) by pol ribozyme. P1 and P2 are the
resulting products after cleavage. Lane 1, ribozyme alone; lane 2,
substrate alone; lane 3, mixture of substrate and ribozyme at time 0;
lane 4, mixture of substrate and ribozyme after 1 min; and lane 5,
mixture of ribozyme and substrate after 5 min. The substrate is 400
nucleotides in length; the ribozyme is 94 nucleotides; and the cleaved
products P1 and P2 are 264 and 136 nucleotides, respectively. MW
indicates molecular sizes in nucleotides.Cleavage in the test-tube provides only a rough ap-
roximation of the true biological potential for a ri-
h
h
r only th
s ght.
176 GIORDANO ET AL.bozyme. Because annealing of substrate RNA to ri-
bozyme is required for cleavage of the former by the
latter, it stands to reason that the volume and the envi-
ronment of confinement for the two RNAs play critical
roles in dictating enzymatic efficiency. Although anti-
HIV-1 ribozymes have been previously explored in solu-
tion and intracellular settings, to date, no intra-HIV-1
virion study of ribozyme activity has been performed.
The 5BD.1 cell line (Srinivasakumar et al., 1997) was
created for efficient packaging of HIV-1 RNA transcribed
from the pTR167 (Fig. 1) vector. pTR167-produced RNA
contains sequences needed for transcription, tRNA
primer binding, dimerization, and packaging, as well as a
hygromycin B resistance gene cassette under the control
of the SV40 early promoter. To ask whether a virion-
FIG. 3. RNA dot-blot analyses of the viral particles obtained after trans
pelleted from the tissue-culture supernatants were processed and trea
membranes in duplicate using a dot-blot manifold. Membranes wer
ecognized either pTR167 and pTR167RibPol vector sequences (A) or
chematic representations of probe hybridizations are shown at the ripackageable pol ribozyme would be more efficacious
than a virion nonpackageable pol ribozyme in inhibiting
p
tHIV-1 infectivity, we inserted a pol ribozyme into nef of
pTR167, generating pTR167RibPol (see Fig. 1 and Mate-
rials and Methods). 5BD.1 packaging cells were trans-
fected with either pTR167 or pTR167RibPol, plus three
additional plasmids (pCMVrev, pCMVtat, and pCMVnef),
which express Rev, Tat, and Nef, respectively. Viral par-
ticles secreted 72 h later into the media from transfected
cells were analyzed by RNA dot-blotting to check for
packaging of RNAs transcribed from pTR167 and
pTR167RibPol (see Fig. 3 and Materials and Methods).
The pol ribozyme sequence packaged specifically into
viral particles was verified by strong hybridization signals
from a ribozyme-specific 32P-probe (Fig. 3B). On the other
and, a control probe specific for pTR167 vector RNA
ybridized equivalently to particles produced from either
the 5BD.1-packaging cells with either pTR167RibPol or pTR167. Virions
h (1) or without (2) RNase, as indicated, and immobilized onto nylon
separately hybridized overnight at 45°C to 32P-labeled probes that
e ribozyme sequence (B). Autoradiographs are shown at the left, andfecting
ted wit
e thenTR167 or pTR167RibPol (Fig. 3A), indicating that the two
ransfections were comparably efficient.
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177ANTI-HIV RIBOZYMETo check whether pTR167RibPol virions are functional,
we assessed the delivery and transduction of pol ri-
bozyme into CD41 cells. pTR167 or pTR167RibPol-pro-
duced particles were inoculated separately onto either
HeLa or HeLa-CD4 cells. Because both the pTR167 and
the pTR167RibPol genomes contain a hygromycin-resis-
tant marker, infectivities could be measured by counting
the number of individual HeLa/HeLa-CD4 colonies that
survived selection by hygromycin B. From results repre-
sentative of three separate assays, we found that pTR167
and pTR167RibPol particles functionally transduced hy-
gromycin B resistance to HeLa-CD4 target cells at an
unconcentrated titer of .7 3 103 and .3 3 103 CFU/ml,
respectively (data not shown). This infectivity was HIV
envelope dependent, because no transduction occurred
for HeLa cells that did not express CD4. Using RT-PCR,
pTR167RibPol-transduced cells were found to express
constitutively pol ribozyme RNAs; the amount of pol ri-
ozyme transcribed from pTR167RibPol in these cells
ncreased, on average, by sixfold when HIV-1 Tat protein
as provided in trans (data not shown).
Virion-packageable ribozyme effectively suppressed a
spreading HIV-1 infection
Previously, we have shown that overexpression of anti-
HIV-1 hammerhead ribozymes can suppress a spreading
viral infection (Dropulic and Jeang, 1994b; Dropulic et al.,
1992; Smith et al., 1997). To determine whether there is a
relative functional advantage for a virion-packageable
pol ribozyme versus its simpler nonpackageable coun-
terpart, several sets of HeLa-CD4 cells were selected
using hygromycin to express either control RNA or vari-
ous forms of pol ribozyme RNA. In total, we surveyed five
differently engineered sets of HeLa-CD4 cells. Thus in
additional to parental HeLa-CD4 cells, we assayed cells
that expressed pTR167 vector RNA alone (HeLa-CD4-
167; Fig. 4A), a packageable pol ribozyme RNA (HeLa-
CD4-167RibPol; Fig. 4A), a nonpackageable pol ribozyme
RNA (HeLa-CD4-RibPolnp; Fig. 4A), or a packageable pol
ribozyme mutant that was catalytically inactivated with a
single point change (HeLa-CD4-167RibPolmut; Fig. 4A).
For the latter three HeLa-CD4 cell types, representative
clones that expressed similar amounts of ribozyme RNAs
(data not shown) were selected for comparison in the
functional assay.
Figure 4 shows representative relative HIV-1 suscep-
tibilities of the five different types of HeLa-CD4 cells.
Identical sets of flasks (0.5 3 106 cells/flask) of the five
(HeLa-CD4, HeLa-CD4-167, HeLa-CD4-167RibPol, HeLa-
CD4-RibPolnp, and HeLa-CD4-167RibPolmut) cell types
were infected with HIV-1 (approximately 0.01 m.o.i.) in
parallel. Relative progression of infection in each of the
cell types was assessed by harvesting infected cells at
the indicated times. HIV-1 infection was quantified by
measuring the amount of integrated proviral DNA (HIV,
p
lFigs. 4A and 4B) using PCR and the amount of particles
produced using a supernatant reverse transcriptase as-
say (Fig. 4C).
Figure 4A is representative of three separate experi-
ments, with each performed on three different clonal cell
lines from the five types of HeLa-CD4 cells. An exami-
nation of the results shows a clear rank order of HIV-1
susceptibility. Replication of virus in the various cells
was HeLa-CD4 5 HeLa-CD4-167 . HeLa-CD4-167Rib-
Polmut . HeLaCD4-RibPolnp . HeLa-CD4-167RibPol.
For example, we observed that HIV-production peaked at
day 3 in vector-derived cells (HeLa-CD4-167), whereas it
peaked to a lower magnitude at day 6 in cells expressing
a nonpackageable ribozyme (HeLa-CD4-RibPolnp) and
to an even lower amount, 3 days later, at day 9 in cells
that expressed the packageable ribozyme (HeLa-CD4-
RibPol; Fig. 4A). Graphic tabulation of densitometric
scanned signals from the cell samplings are presented
in Fig. 4B. These results are consistent with an inhibitory
effect from a nonpackageable pol ribozyme and a greater
anti-HIV-1 effects from a virion-packageable pol
ribozyme. Supernatant RT results from day 3 and day 6
postinfection (Fig. 4C) are also consistent with a greater
antiviral effect from a packageable ribozyme. Further-
more, single round infectivity assays using MAGI cells
(Kimpton and Emerman, 1992) further support the results
derived from spreading virus infections. For example,
infections of MAGI cells with viruses produced from
cotransfection of pNL4-3 with either a packageable or a
nonpackageable pol ribozyme produced, on average,
hree or four times fewer blue cells in the former com-
ared with the latter (data not shown).
ntravirion cleavage of HIV-1 RNAs
It is important to determine whether the increased anti-
iral effect for a packageable ribozyme stems from catalytic
ctivity within viral particles. To address this, we queried for
vidence of intravirion cleavage of HIV-1 RNAs. Viral parti-
les were harvested from RT-normalized supernatants from
ach of the indicated cell types infected with HIV-1 (Fig. 5).
T-PCR was performed to compare the HIV-1 RNA con-
ained within the variously produced virion particles. We
ought to ascertain two points. First, we wanted to compare
he relative amounts of HIV-1 RNA per arbitrary unit of virion
roduced from the different HeLa-CD4 cell types. For this,
e analyzed equal amounts of RT-normalized virions by
T-PCR using primers complementary to a conserved re-
ion in vpr (Fig. 5A, right schematic). Results from this
nalysis indicated that compared with HeLa-CD4-167 cells
Fig. 5A, lane 2), HeLa-CD4-RibPolnp cells produced parti-
les with a slightly (approximately twofold) reduced amount
f HIV-1 genomic RNA (Fig. 5A, lane 3), whereas HeLa-
D4-RibPol cells produced virions with a significantly (ap-
roximately 40-fold) reduced amount of HIV-1 RNA (Fig. 5A,
ane 4). Second, we asked whether the reduction observed
e
a RibPoln
s d 167R
178 GIORDANO ET AL.with HeLa-CD4-167RibPol cells could be a consequence of
the virion incorporation of packageable pol ribozyme.
Whether pol ribozyme RNA sequence was present in any of
the virions shown in Fig. 5A was addressed with a second
set of primers that recognize only the ribozyme RNA (Fig.
FIG. 4. Relative replication of HIV-1 in various HeLa-CD4 cells that e
ribozyme (167RibPolnp), or a catalytically inactive pol ribozyme mutan
monitored by PCR analyses of integrated proviral DNAs at the indicate
shown to illustrate the reproducibility of the infections and the PCR
PCR-amplified to serve as a normalizing control. Cells were inoculated
days postinfection, equal numbers of cells were lysed and proviral
electrophoresed in agarose gels, transferred to membranes, and then
xperiments performed on at least three independently isolated cell lin
rbitrary units from HeLa-CD4, HeLa-CD4-167RibPolmut, HeLa-CD4-
upernatant RT values from HeLa-CD4, 167RibPolmut, 167RibPolnp, an5B, right schematic). This second RT-PCR assay performed
on RT-normalized virions from HeLa-CD4, HeLa-CD4-167,HeLa-CD4-RibPolnp, and HeLa-CD4-167RibPol cells re-
vealed a correctly sized 180-bp band only in the HeLa-CD4-
167RibPol-produced sample (Fig. 5B, lane 4). Thus the re-
duction of HIV-1 genomic virion RNA shown in Fig. 5A (lane
4) correlated with the intravirion presence of pol ribozyme
a virion-packageable pol ribozyme (167RibPol), a nonpackageable pol
ibPolmut). (A) Viral loads in each of the tissue culture infection were
postinfection. Four different experiments with HeLa-CD4-167 cells are
ses. In all cases, the b-globin gene in each cell sample was also
ual amounts of pNL4-3 virus, normalized by RT activity. At the indicated
as PCR-amplified using specific primers. The amplified DNAs were
zed with an HIV-1-specific 32P-probe. The results are representative of
each cell type. (B) A representative graph of densitometric values in
p, and HeLa-167RibPol cells. (C) Representative day 3 and day 6
ibPol cells.xpress
t (167R
d days
analy
with eq
DNA w
hybridi
es from(Fig. 5B, lane 4).
The above correlation of reduced HIV-1 genomic RNA
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179ANTI-HIV RIBOZYMEwith virion-associated pol ribozyme suggests that intra-
irion cleavage of the former was effected by the latter.
o assess this possibility, we next asked whether evi-
ence for pol ribozyme-specific cleavage of HIV-1
enomic RNA within virions could be verified. Thus an
lternate RT-PCR analysis of virion RNA was designed.
o characterize whether site-specific cleavage of HIV-1
enomic RNA has occurred, three primers (a, b, and c;
ig. 6A) were simultaneously used in a single PCR. The
hree primers were such that primer a (sense) annealed
istally “upstream” of the putative pol ribozyme cleavage
ite, whereas primer b (antisense) annealed proximally
upstream” of the cleavage site and primer c (antisense)
nnealed “downstream” of the cleavage site. Based on
heir locations, the a-b amplification (150 bp) is, in prin-
iple, insensitive to pol ribozyme cleavage, whereas a-c
mplification (320 bp) would be hindered by pol ribozyme
FIG. 5. RT-PCR analyses of viral RNAs isolated from HIV-1 virions p
produced from each cell type were processed for RNA isolation. The RN
or ribozyme-specific primers (bottom). The amplified samples were
hybridization using an HIV-1-specific probe (top) or a ribozyme-specifileavage of HIV-1 genomic RNA.
When virion RNAs produced from either HeLa-CD4-
c
TibPolnp or HeLa-CD4-167RibPol cells were compared,
e appreciated visually that the ratio of a-c-generated to
-b-generated products was less in the latter than in the
ormer (Fig. 6B). Quantitative densitometric scans (Figs.
C and 6D) indicated that after normalizing to a-b prod-
cts, HeLa-CD4-167RibPol virions had roughly one third
he amount of a-c products found for HeLa-CD4-RibPolnp
irions. Considered together with the data in Fig. 5, these
esults suggest that virion-associated pol ribozyme can
indeed perform site-specific cleavage within viral parti-
cles. Under these conditions, intravirion cleavage of
HIV-1 genomic RNA by pol ribozyme was nonquantitative
ecause some a-c products remained detectable.
DISCUSSION
Currently accepted chemotherapeutics for HIV-1 in-
d from the various HeLa-CD4 cell lines. RT-normalized virus particles
les were PCR amplified using either HIV-1 vector-specific primers (top)
ed by agarose gel electrophoresis and subjected to Southern blot
(bottom).roduce
A samplude reverse transcriptase and protease inhibitors.
hese have excellent short-term efficacy but as yet un-
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180 GIORDANO ET AL.certain long-term benefits. Evolution of resistant viruses
and the finding of latent HIV-1 infection of cells (Finzi et
al., 1997) suggest that additional molecular therapeutics
hould be explored as potential adjuncts to chemother-
peutics. Several molecular antivirals, including ri-
ozymes, have been shown to be efficacious for ex vivo
uppression of HIV-1 replication in tissue culture (re-
iewed in Dropulic and Jeang, 1994). More recently, a
hase I in vivo clinical trial of ribozymes has begun for
HIV-1-seropositive individuals (Wong-Staal et al., 1998).
Ribozymes are effectors that can down-regulate gene
expression by site-specific cleavage of RNAs (e.g., Cech,
FIG. 6. Intravirion cleavage of HIV-1 RNA. (A) Schematic depiction of
rimer pairs can amplify uncleaved RNA, whereas the ac primer pair c
ersus ac is a reflection of cleavage. (B) Autoradiogram comparing
67RibPolnp versus HeLa-CD4-167RibPol cells. Note relative differences
compared with the nonpackaging pol ribozyme showed a decrease in
ac and the ab fragments using phosphorimaging/densitometry. Due to
RT units, five times more 167RibPol particles were compared with 1671993; Homann et al., 1993; Kashani-Sabet et al., 1992,
1994). To effect cleavage, ribozymes must hybridize totheir target RNAs. Within biological compartments, unlike
the simple RNA–RNA hybrids modeled in test-tube solu-
tions, ribozyme–target interactions are influenced by
many factors. Some of these factors include (1) subcel-
lular colocalization of ribozyme with target RNA (re-
viewed in Sullenger, 1995), (2) ability of ribozymes to
hybridize with highly secondary structured target RNAs,
and (3) the positive and negative effects of RNA-binding
proteins on ribozyme–target interactions. Thus although
ribozyme–target cleavages are frequently shown to be
very efficient in test-tube scenarios, in many biological
settings it has been suggested that for the ribozyme to
- PCR assay for cleaved and uncleaved RNAs. Both the ab and the ac
mplify cleaved RNA. Thus a comparison of the relative signal from ab
mplified fragments from HIV particles from infection of HeLa-CD4-
ratio of uncleaved (ac) to total (ab) RNA. The packageable pol ribozyme
ount of ac fragment compared with ab. (C and D) Quantification of the
uced amounts of viral RNA in 167RibPol virions (see Fig. 5), based on
p particles in the RT-PCR assays.the RT
annot a
PCR-a
in the
the amachieve 50% sequestration of its target RNA, the former
should be present at a 600- to 2800-fold stoichiometry to
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181ANTI-HIV RIBOZYMEthe latter (Wang and Dolnick, 1993; Dropulic and Jeang,
1994).
In considering how ribozyme and target RNA might
pair with each other, there are, in principle, two simple
ways for promoting RNA-RNA annealing: (1) to increase
the amount of expressed RNAs per volume of confine-
ment or (2) to keep the amount of RNA constant and
reduce the volume of confinement. To date, with one
exception (Sullenger and Cech, 1993), in studies of anti-
viral effects of ribozymes, the volume of confinement has
been restricted to the virus-infected cell. A purpose of the
present study was to compare whether the same anti-
HIV ribozyme would have greater efficiency if it were
targeted to the (smaller) virion as opposed to the (larger)
infected cell.
The HIV vector pTR167 and the 5BD.1 packaging cells
(Srinivasakumar et al., 1997) provided the requisite re-
agents necessary to create a virion-targeted ribozyme.
Into pTR167, a short hammerhead catalytic motif targeted
to a single site in the pol gene (pTR167RibPol; Fig. 1) was
incorporated. Within the context of pTR167RibPol trans-
fected into 5BD.1 cells, it was anticipated that a pol
ribozyme RNA would be incorporated into HIV-1 virions.
Indeed in Figs. 3 and 5, this supposition was directly
verified.
Whether a packageable ribozyme has additive anti-
HIV-1 functional use when compared with its counterpart
that is identical for cleavage but cannot be incorporated
into virions was explored in a spreading HIV-1 assay in
HeLa-CD4-derived cells. In side-by-side comparisons,
we observed that a cleavage-competent but packaging-
incompetent ribozyme was less efficient than its virion-
packaged counterpart for suppressing HIV-1 viral load in
tissue culture (Fig. 4). Thus within the parameters of our
experiments, the former permitted virus production to
peak at a higher amount 3 days earlier (on day 6) in
tissue culture than the latter (on day 9; Fig. 4A). Previ-
ously, in a study of viral replication kinetics, Dimitrov et
al. (1993) suggested that every 10-fold reduction in the
titer of viral inoculum resulted in a 3-day delay in the
peak appearance of virus in tissue culture (e.g., if inoc-
ulation of cells with 105 infectious units produced a virus
eak on day 6, then inoculation of the same cells with 104
units would produce a virus peak on day 9). Hence,
roughly based on the relationship between virus kinetics
and virus titer in tissue culture as suggested by Dimitrov
et al. (1993), one could interpret that a virion-package-
able ribozyme is 10-fold better at suppressing HIV-1
replication than the same ribozyme that could not be
packaged into virions.
Should one accept that ribozymes deserve consider-
ation as a possible molecular antiviral adjunct for HIV-1,
then one would like to develop the optimal form of ri-
bozyme for in vivo application. Based on our results, itould be argued that regardless of the type of catalytic
otif (e.g., hairpin versus hammerhead) used or the site
d
fo which a ribozyme might be directed, for HIV-1, target-
ng a ribozyme into virions would be more functionally
ffective than targeting the same ribozyme into infected
ells. (Parenthetically, ribozymes that are virion targeted
an also function within infected cells, whereas ri-
ozymes that do not have packaging sequences cannot
ocate into virions; Fig. 5B.) Our observations for HIV-1
re fully consistent with findings previously proposed by
ullenger and Cech (1993) using murine retroviral 2lac Z
ectors.
MATERIALS AND METHODS
lasmids
A synthetic oligonucleotide containing a hammerhead
ibozyme motif directed to a cleavage site in the HIV-1
ol sequence [59-ATGCCAGGTACCTGATGAGGCCGAA-
GGCCGAAAATTTTTCCTTTTTTAT-39] was inserted into
he HindIII and BamHI sites of pGEM-4Z vector (Pro-
ega, Madison, WI). The resulting pGEM-4Z-RibPol plas-
id was used for in vitro transcription of ribozyme RNA.
he same oligonucleotide was also ligated into the XhoI
ite in the nef gene of an HIV-1 molecular vector, pTR167
(Rizvi and Panginabin, 1993), to create pTR167RibPol
(Fig. 1). To generate a counterpart ribozyme that lacks an
HIV-1 packaging signal, the HindIII–BamHI fragment,
which encompasses the ribozyme motif in pTR167RibPol,
was isolated and ligated into expression vector pBK-
CMV (Stratagene, La Jolla, CA). As a comparative control,
a previously described mutation (Dropulic et al., 1992)
was introduced into the catalytic motif of the ribozyme
contained in pTR167RibPol, generating a molecular vec-
tor that expresses a packageable but otherwise inactive
ribozyme (pTR167RibPolmut).
In vitro assays
pGEM-4Z-RibPol contains a pol-specific ribozyme,
whereas plasmid pGEM-4Z-Pol has a fragment (nucleo-
tides 4020–4403) of pol from pNL4-3 (Adachi et al., 1986)
hat contains the cleavage site for the pol-specific ri-
ozyme. For transcription into RNA, both plasmids were
inearized with appropriate enzymes (EcoRI or NcoI, re-
pectively), and the linearized templates were tran-
cribed into radiolabeled RNAs using T7 RNA polymer-
se as previously described (Dropulic et al., 1992).
riefly, 0.5 mg of DNA was added to 20 U of RNasin, 50
mCi of [a-32P]UTP, 2.5 mM ATP, 2.5 mM GTP, 2.5 mM CTP,
00 mM dithiothreitol, and 20 U of T7 RNA polymerase in
3 transcription buffer (40 mM Tris–HCl, pH 7.5, 6 mM
gCl2, 2 mM spermidine, and 10 mM NaCl). The reaction
as conducted for 60 min at 37°C; EDTA was added to
mM, halting the reaction by sequestering free magne-
ium. Specific activity of the generated RNA probe was
etermined by precipitation with 5% trichloroacetic acid,
ollowed by scintillation counting. After transcription, re-
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182 GIORDANO ET AL.sidual DNA template was removed by digestion with 1 U
of RQ1 RNase-free DNase (Promega) for 15 min at 37°C.
To assay for activity, equal amounts of ribozyme and
substrate were mixed in a magnesium-free buffer,
heated to 65°C for 5 min, and cooled stepwise to 37°C in
a water bath (30 s each at 55°, 42°, and 37°C). The
reaction mixture was then adjusted to 20 mM MgCl2 to
initiate enzymatic activity. After 1 or 5 min, the reaction
was stopped by the addition of formamide and then
boiled for 3 min and analyzed in an 8% denaturing poly-
acrylamide gel.
Cell culture
Cells were maintained in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum, 100 U/ml peni-
cillin, 100 mg/ml streptomycin, and 2 mM glutamine. Cell
lines stably expressing HIV structural proteins were
maintained as described previously (Saiki et al., 1988).
HeLa-CD4 (clone 6C/HT-6C; Chesebro and Wehrly, 1988)
was provided from the AIDS Research and Reference
Reagent Program (National Institutes of Health).
Transient transfection of packaging cells and
infection of target cells
The 5BD.1 HIV-1-packaging cell line constitutively ex-
presses HIV-1 structural proteins (Srinivasakumar et al.,
997). Packaging cells were transfected using calcium
hosphate (Graham and Van der Eb, 1973; Hammar-
kjold et al., 1986) to produce vector stocks. Typically a
00-mm plate of cells was transfected with 5 mg of HIV
lasmid (pTR167 or pTR167RibPol) and pCMV vectors
xpressing the HIV regulatory proteins (Tat, Rev, and
ef). Supernatants were harvested at 72 h posttransfec-
ion, centrifuged at 3000 rpm at 4°C for 15 min, and
urther clarified by filtration through 0.45-mm mem-
branes.
To infect HeLa-CD4 cells with the HIV vector stocks,
clarified supernatants were 10-fold serially diluted into
complete medium. DEAE-dextran was added to each
dilution to a final concentration of 8 mg/ml to facilitate
iral absorption. Then 1 ml of each dilution was added to
60% confluent 60-mm dish of cells that had been
reshly subcultured the previous day. The inoculum was
dsorbed to cells for 4 h at 37°C, after which 4 ml of
omplete medium were added. After 48 h, the medium
as replaced with medium containing 200 mg/ml hygro-
mycin B (Srinivasakumar et al., 1997). Fourteen days
later, drug-resistant colonies were counted. Several in-
dependent colonies were isolated and subcultured.
RNA dot-blot analysis
5BD.1 packaging cells were transfected to produce
vector stocks as described elsewhere (Srinivasakumar
et al., 1997). Supernatants, harvested at 72 h posttrans-
fection, were first centrifuged at 3000 rpm at 4°C for 15min and then filtered through 0.45-mm membranes. Next,
he clarified supernatants were further centrifuged for 45
in at 100,000 3 g in an SW55 rotor (Beckman) to pellet
virions. The pellets were resuspended into buffer con-
taining 10 mM Tris–HCl (pH 7.4), 100 mM NaCl, and 5 mM
MgCl2; disrupted by incubation with 1% Nonidet P-40 for
0 min at 37°C in the presence of 100 U of rRNasin
Promega); and followed by the addition of 30 ml of 203
SC (13 SSC 5 0.15 M NaCl plus 0.015 M sodium citrate)
and 20 ml of formaldehyde. The samples were then
heated to 60°C for 15 min, diluted with 2 volumes of
ice-cold 203 SSC, and immobilized onto nylon mem-
branes using a dot-blot manifold. Membranes were hy-
bridized overnight at 45°C to 32P-labeled HIV-specific
NA probe and processed for autoradiography as pre-
iously described (Kiernan et al., 1998).
NA PCR
HIV-1 stocks were obtained by transfecting HeLa cells
ith the pNL4-3 molecular clone (Adachi et al., 1986).
iral stocks, normalized for RT, were used to indepen-
ently infect subcultured hygromycin-resistant HeLa-
D4 clonal cell lines (as indicated in the figures). For
nfections, cells were washed three times in PBS and
esuspended for 3 h at 37°C in complete medium con-
aining the appropriate virus inoculum. Cells were then
ashed to remove the viral inoculum, and incubation in
irus-free complete medium was continued. At the indi-
ated time postinfection, samples of cells were har-
ested, washed in PBS, lysed, and digested with protein-
se K as described previously (Kiernan et al., 1998).
IV-specific DNA sequences in the cell samples were
mplified by PCR. PCRs (50 ml) contained 10 ml of cell
ysate, 0.2 mM deoxynucleoside triphosphates, 1 mM
oncentration of primers, 1.5 mM MgCl2, 10 mM Tris–HCl
pH 8.0), 50 mM KCl, and 1.25 U of Taq polymerase
Boehringer Mannheim) and were conducted for 30 cy-
les at an annealing temperature of 60°C. Primer pairs
ere: 59-ATGAAGCCCCAGACC (sense) and 59-GGATC-
ACTGGCTCC (antisense). PCR products were electro-
horesed in 1.5% agarose gels, denatured in 0.4 M
aOH–1.5 M NaCl, transferred to Hybond-N1 (Amer-
ham), and hybridized with 32P-labeled oligonucleotides
ollowed by autoradiography. To ensure readouts in the
inear range, reactions were repeated several times on
erial dilutions of cell lysates. For purposes of signal
ormalization, PCR amplifications of human b-globin se-
uence in the same cell samples were performed in
arallel. b-Globin primers (RS79/80) have been de-
scribed previously (Homann et al., 1993; Saiki et al.,
1988).
RNA PCRViral RNAs were isolated from infected HeLa-CD4
cells with the QIAamp Viral RNA Kit (Qiagen, Studio City,
AB
183ANTI-HIV RIBOZYMECA) according to manufacturer’s protocol. RT-PCR was
performed according to Ezr Tth RNA PCR protocol (Per-
kin–Elmer Cetus, Norwalk, CT). RT-PCR products were
electrophoresed and visualized as described above.
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